Acute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT
|
|
- Percival Grant
- 6 years ago
- Views:
Transcription
1 Acute coronary syndromes A European viewpoint Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT
2 Potential conflicts of interest In the past 2 years Felicita Andreotti has received fees for lectures, advising or monitoring activities from Amgen, Bayer, Bristol-Myers Squibb / Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly Speaker
3 3 Eur Heart J 2016 Jan 14;37(3):
4 Initial assessment of patients with suspected acute coronary syndromes <10 min Emergency Echo in acute HF pts to assess LV and valve fx & exclude mechanical complications IC
5 What else is new 1 - High-sensitivity cardiac troponin diagnostic algorithm 2 - Revascularization Criteria mandating indication/timing of invasive strategy 3 - Antithrombotic treatment Timing of P2Y12 inhibitor for early invasive strategy (pretreatment) 4 - Antithrombotic treatment: With long-term oral anticoagulants 5 - Revascularization: Radial approach and DES 6 - Rhythm monitoring guide 7 - Antithrombotic treatment: Duration of dual antiplatelet therapy 8 - Section on elderly (web addenda) 9 - Secondary prevention: Lipid lowering beyond statins 10- «Questions and Answers» companion
6 Guidance on hs-ctn for suspected NSTEMI > obtain sensitive or high sensitivity (hs)-ctn <60 min... IA > use 0-3h protocol with hs-ctn... IB > use validated 0-1h hs-ctn algorithm and repeat at 3-6h if inconclusive or suggestive. IB Very Low or Low and No 0-1h High or 0-1h Predictive values for acute MI: negative >98% - positive 75-80%
7 0-1h rule-in and rule-out hs-ctn algorithms Cut-offs are assay specific
8 Invasive strategy and timing based on initial risk (2011: primary/ secondary high-risk criteria) <2h, IC Ongoing ischaemia Immediate action <24h, IA <72h, IA +, IA
9 P2Y12 inhibitor before early invasive strategy (2011: as soon as possible ) As the optimal timing of ticagrelor or clopidogrel administration in NSTE-ACS patients scheduled for an invasive strategy has not been adequately investigated, no recommendation for or against pretreatment with these agents can be formulated. In patients not scheduled for an invasive strategy, P2Y12 inhibitor recommended as soon as diagnosis established (and ticagrelor preferred over clopidogrel in absence of increased bleeding risk) Eur Heart J 2016 Jan 14;37(3):
10 Oral anticoagulation plus antiplatelet(s) Eur Heart J 2016 Jan 14;37(3):
11 Selection of NSTE-ACS treatment strategy and timing according to initial risk stratification 11 IC IA IA IA (MDCT angio if ECG or ctn inconclusive, IIa A)
12 Radial approach It is recommended that centres treating ACS patients implement a transition from transfemoral to transradial access. Proficiency in the femoral approach should be maintained (e.g. for IABP insertion and structural as well as peripheral procedures) Eur Heart J 2016 Jan 14;37(3):
13 MATRIX Co-primary composite outcomes at 30 days 13 All-cause mortality, MI, stroke N=8404 NSTE-ACS + STEMI Radial vs. femoral All-cause mortality, MI, stroke, or BARC 3 or 5 bleeding Valgimigli M et al. Lancet. 2015;385: Speaker
14 Radial vs femoral meta-analysis RR (95% CI) P Non-CABG major bleeeds Death, MI, or stroke Death MI Stroke Valgimigli M et al. Lancet 2015;385:
15 Drug-eluting stents Eur Heart J 2016 Jan 14;37(3):
16 Antiplatelet therapy after stenting on OAC
17 Time from PCI/ACS NSTE-ACS patients with non-valvular atrial fibrillation Management strategy PCI Medically managed /CABG Bleeding risk Low to intermediate (e.g. HAS-BLED = 0 2) High (e.g. HAS-BLED 3) 0 4 weeks 6 months IIaC Triple therapy O A C Dual therapy b Triple or dual therapy a O A C Dual therapy b O C or A IIaC Dual therapy b O C or A 12 months O C or A Lifelong O Monotherapy c Oral anticoagulation O A ASA mg daily C (VKA or NOACs) Clopidogrel 75 mg daily Adapted from Lip et al. Eur Heart J 2014;35: a Dual therapy with oral anticoagulation and clopidogrel may be considered in selected patients (low ischaemic risk). IIb B b aspirin as an alternative to clopidogrel may be considered in patients on dual therapy (i.e., oral anticoagulation plus single antiplatelet); triple therapy may be considered up to 12 months in patients at very high risk for ischaemic events. c Dual therapy with oral anticoagulation and an antiplatelet agent (aspirin or clopidogrel) beyond one year may be considered in patients at very high risk of coronary events. In patients undergoing coronary stenting, dual antiplatelet therapy may be an alternative to triple or dual therapy if the CHA2DS2-VASc score is 1 (males) or 2 (females).
18 Guidance on rhythm monitoring Continuous monitoring up to diagnosis (Y/N) IC IIa C * IIa C IIb C in suspected spasm * H A E R S C Eur Heart J 2016 Jan 14;37(3):
19 Duration of dual antiplatelet therapy Eur Heart J 2016 Jan 14;37(3):
20 Elderly with NSTE-ACS was B 2 RCTs - TACTICS - Elderly Eur Heart J 2016 Jan 14;37(3):
21 Antithrombotic therapy in the elderly Major RCT testing drugs shown in figure Age-stratified ischaemic and bleeding event rates Expert position on treatment in the elderly Andreotti F et al. ESC Thrombosis WG. Eur Heart J 2015;doi: /eurheartj/ehv304 Eur Heart J 2016 Jan 14;37(3):
22 40 cases each No reference Link to the dedicated sections of the GL Help to implement GL in daily practice 22 European Heart Journal doi: /eurheartj/ehv409 European Heart Journal doi: /eurheartj/ehv407 European Heart Journal doi: /eurheartj/ehv408 Speaker
23
24 ABSTRACT SUBMISSION Mid December 14 February 2016 CLINICAL CASE SUBMISSION Mid January 1 March 2016 HOT LINES SUBMISSION Mid March 1 May 2016 EARLY REGISTRATION Deadline: 31 May 2016 LATE REGISTRATION Deadline: 31 July
2015 ESC Guidelines for the Management of ACS in Patients presenting without Persistent ST-Elevation
ESC/Saudi Heart Association Joint Meeting Dammam, November 14-15, 2015 2015 ESC Guidelines for the Management of ACS in Patients presenting without Persistent ST-Elevation Francesco Cosentino, MD, PhD,
More information2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation Thierry Gillebert European Society of Cardiology, Slides kindly provided
More informationSCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable?
SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable? tielle est 2 ré Totielle est interdite. Prof. Marco Roffi Hôpitaux Universitaires de Genève Research funding
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationAntithrombotic therapy in CAD patients with concomitant NAFV: why and for whom?
Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom? Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Patients (%) Patients
More informationTriple Therapy After PCI in AF: A Quagmire Soon to be Drained
Triple Therapy After PCI in AF: A Quagmire Soon to be Drained Freek W.A. Verheugt Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) Amsterdam, Netherlands DISCLOSURES FOR FREEK W. A. VERHEUGT
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationStudy design: multicenter, randomized, open-label trial following a PROBE design
Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationEuropean Heart Journal 2015 doi: /eurheartj/ehv320
European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 1 2 Clinical implications of high-sensivity troponin assays European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 Conditions other than Type
More informationΣτεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές
4 ο ΠΑΝΕΛΛΗΝΙΟ ΑΡΡΥΘΜΙΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ 21-22 ΣΕΠΤΕΜΒΡΙΟΥ 2018 HILTON, ΑΘΗΝΑ Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές Ι. Κανακάκης MD, PhD Διευθυντής Αιμοδυναμικού Τμήματος
More informationWHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.
TAVI WITH ATRIAL FIBRILLATION: WHICH ANTITHROMBOTIC REGIMEN? G. MONTALESCOT (PARIS, FR) Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France www.action-cœur.org Dr. Montalescot
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationDr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου
Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Θεσσαλονίκη, 9/2/2018 Disclosures: None Primary efficacy outcome* (%/year) Antiplatelet Therapy
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationNorth Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease
Guidelines on oral antiplatelet therapy in cardiovascular disease This guidance should be considered as one part of the wider therapeutic management of patients. The indication for antiplatelet therapy
More informationHigh-sensitive troponin. Introduction. Platelet aggregation inhibition at admission
Neth Heart J (2017) 25:181 185 DOI 10.1007/s12471-016-0939-y GUIDELINES 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:
More informationScope of the Problem: DAPT and Triple Therapy after Stenting
Scope of the Problem: DAPT and Triple Therapy after Stenting Kurt Huber, MD, FESC, FACC 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Session, August 30, 2010,
More informationFølgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved
. Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved tilladelse Antithrombotic therapy in Atrial Fibrillation
More informationDual Antiplatelet Therapy: Time for a Paradigm Shift?
Dual Antiplatelet Therapy: Time for a Paradigm Shift? 5 years after PLATO Experience from the Daily Clinical Practice Hans Rickli Goals with antithrombotic treatment Acute coronary syndrome Risk reduction
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationHEART OF THE MATTER: cardiac issues in safe endoscopy & sedation
HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationNAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING
NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING Snehal H. Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AACC Associate Professor of Pharmacy Practice MCPHS
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationDual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015
Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015 Wesam A Alhejily MD FRCPC FACP FACC FSCAI Assistant Professor of Medicine Chief Of Adult Cardiology Consultant
More informationManuel Castella MD PhD Hospital Clínic, University of
Manuel Castella MD PhD Hospital Clínic, University of Barcelona mcaste@clinic.ub.es @mcastellamd www.escardio.org/guidelines European Heart Journal - doi:10.1093/eurheartj/ehw210 Providing integrated care
More informationState of the Art in the ACS Atrial Fibrillation Overlap Syndrome
State of the Art in the ACS Atrial Fibrillation Overlap Syndrome C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division
More informationTailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI
Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI Adel El-Etriby; MD Professor of Cardiology Ain Shams University President of the Egyptian Working Group of Interventional Cardiology
More informationAnti-thrombotic treatment after TAVR: insights from the FRANCE-TAVI Registry
Anti-thrombotic treatment after TAVR: insights from the FRANCE-TAVI Registry Pavel OVERTCHOUK Paul GUEDENEY Stéphanie ROUANET Jean Philippe VERHOYE Thierry LEFEVRE Eric VAN BELLE Helene ELTCHANINOFF Martine
More informationIschemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland
Ischemic and bleeding risk stratification in NSTE ACS Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland Disclosure Andrzej Budaj, MD, PhD, reports the following potential conflicts
More informationRobert C. Welsh, MD, FRCPC Professor of Medicine, University of Alberta Zone Clinical Department Head, Cardiac Sciences
Managing Atrial Fibrillation and ACS/PCI Applying New Evidence to Clinical Practice Dual Anti-Thrombotic Therapy in Acute Coronary Syndromes (ACS) and Afib + PCI/ACS Patients Robert C. Welsh, MD, FRCPC
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationTRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital
TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationImpact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy
Impact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationPlatelet inhibition PLUS low-dose anticoagulation a new paradigm for all PAD patients?
Platelet inhibition PLUS low-dose anticoagulation a new paradigm for all PAD patients? Thomas HW Stadlbauer, MD Klinikum rechts der Isar, Technical University of Munich Disclosure Speaker name: Thomas
More informationAntithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France
Antithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France Disclosures Research grants: Astra-Zeneca, Merck, Novartis, Pfizer, sanofi-aventis, Servier, The MedCo Fees
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More information8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific
More informationThrombin Receptor Antagonists and Other New Oral Antiplatelets Drugs
Thrombin Receptor Antagonists and Other New Oral Antiplatelets Drugs David J. Moliterno, MD Professor and Chairman Department of Internal Medicine The University of Kentucky Linda and Jack Gill Heart Institute
More informationDays
Post ACS Care 2013 Clinical dilemmas Christopher Granger, MD Professor of Medicine Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationUpstream P2Y 12 RB. Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia
Upstream P2Y 12 RB Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia Dio può essere dimostrato Le dimostrazioni dell esistenza di Dio IA Dio non può essere dimostrato
More informationISCHEMIC HEART DISEASE
ESC CONGRESS HIGHLIGHTS ISCHEMIC HEART DISEASE Francesco Cosentino (Stockholm, S) Declaration of Interest Advisory Board/Speaker: AstraZeneca, Roche, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck,
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationAdditional Contributor: Glenn Levine (USA).
2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the Management
More informationAnticoagulants and antiplatelet therapy in the older patient: Choosing wisely
Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Rajiv Gulati, MD PhD Advances in Cardiac Arrhythmias & Great Innovations in Cardiology Torino, October 2015 2015 MFMER 3477310-1
More informationΑντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)
Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο) Dimitrios Alexopoulos, MD, FESC, FACC Cardiology Department, Patras University Hospital, Patras, Rio, Greece. Patras University Hospital I, Dimitrios
More informationPRACTICAL MANAGEMENT OF NOAC s December 8,
PRACTICAL MANAGEMENT OF NOAC s December 8, 2017 1 Faculty Disclosure Faculty: John Eikelboom MBBS, MSc, FRCPC Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Career Award, Heart and Stroke Foundation
More informationSTEMI Linee guida ESC Maddalena Lettino, Italy
STEMI Linee guida ESC 2017 Maddalena Lettino, Italy Disclosure Speaker fee: Aspen, Astra Zeneca, BMS, Boehringer, Eli Lilly, DaichiiSankio, Bayer, Pfizer, Sanofi Advisory board member: Astra Zeneca, Eli
More informationRecognizing the High Risk NSTEMI Patient for Early Appropriate Therapy
Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Learning Objectives Learn to recognize the high risk patient Discuss effective management of a high risk NSTEMI patient Review CCS
More informationA.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
More informationThe Korean Society of Cardiology COI Disclosure
The Korean Society of Cardiology COI Disclosure Name of First Author: Yongwhi Park The authors have no financial conflicts of interest to disclose concerning the presentation 2017 Annual Spring Scientific
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Chairpersons Christian W. Hamm Medical Clinic
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationSHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?
SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI? Kurt Huber, MD 3 Department of Internal Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria Disclosures DISCLOSURE
More informationAcute Coronary syndrome
Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood
More informationNon ST Elevation-ACS. Michael W. Cammarata, MD
Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationThe following is a transcript from a multimedia activity. Interactivity applies only when viewing the activity online.
Presentation 1 The following is a transcript from a multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by an educational grant from Daiichi Sankyo
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationSpeaker s name: Thomas Cuisset, MD, PhD
Speaker s name: Thomas Cuisset, MD, PhD X I have the following potential conflicts of interest to report: x Consulting: Daiichi Sankyo, Eli Lilly Employment in industry Stockholder of a healthcare company
More informationCURRENT OPINION. European Heart Journal (2014) 35, doi: /eurheartj/ehu298
European Heart Journal (2014) 35, 3155 3179 doi:10.1093/eurheartj/ehu298 CURRENT OPINION Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or
More informationManagement of Coronary Artery Disease including Stable and Acute Coronary Syndromes
Management of Coronary Artery Disease including Stable and Acute Coronary Syndromes Dr Sukhjinder Nijjer Consultant Cardiologist Chelsea & Westminster NHS Foundation Trust Imperial College Healthcare NHS
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationTriple antithrombotic therapy following an acute coronary syndrome
Triple antithrombotic therapy following an acute coronary syndrome prevalence, outcomes and prognostic utility of the HAS- BLED score Presented by: Nouf alanazi Supervised by: Dr.Khalid Alhabib Scenario
More informationDepartment of Medicine III, Martin Luther-University Halle, Germany b. Unità Operativa di Cardiologia, Ospedale Maggiore, Bologna, Italy c
Comparison of CHADS 2 -Score with CHA 2 DS 2 VASc-Score in a prospective multicenter registry on patients with atrial fibrillation undergoing coronary artery stenting -First results from the AFCAS-trial-
More informationThe Great debate: thrombocardiology post-compass
The Great debate: thrombocardiology post-compass Anticoagulation should replace antiplatelets in CAD prevention - CON Jean-Philippe COLLET Jean-philippe.collet@psl.aphp.fr Sorbonne Université_Action Study
More informationAdjunctive Pharmacotherapy: Current Landscape for Patients Post TAVR
Adjunctive Pharmacotherapy: Current Landscape for Patients Post TAVR George D. Dangas, MD, FACC, FAHA, FESC, MSCAI Professor of Medicine & Surgery Icahn School of Medicine at Mount Sinai The Mount Sinai
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationVirchow s triad in AF
1- Pathophysiology 2- Atrial Fibrillation Thrombogenesis Prevention (OAC / APA) 3- Thrombogenesis in AF complicating ACS Prevalence Consequences 4- PCI (with stents) PCI and antithrombotic treatment 5-
More information